Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Trajan Group Holdings Limited (TRJ.AX)
Ringwood, VIC, AU
Headquartered in Ringwood, Australia, and established in 2011, Trajan Group Holdings Limited is a global enterprise focused on designing, manufacturing, marketing, and distributing a diverse range of analytical and life science instruments and associated products. Its extensive operations cover Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company's activities are organized into two main divisions: Analytical Products and Life Science Solutions. The Analytical Products segment provides essential components such as syringes, GC consumables, septa, caps, liners, gas filters, and tubing. It also supplies pathology and sampling equipment, along with automated systems tailored for examining biological, food, and environmental samples. Complementing this, Trajan delivers nutrition testing solutions for various clients, including pathology laboratories, research and clinical trial initiatives, personalized nutrition programs, corporate wellness strategies, and health insurance providers. The company's offerings further extend to automation workflow solutions, micro-sampling devices, and comprehensive data analysis services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.47% | +11.67% | -10.67% | -37.96% | -50.00% | -52.14% | -56.21% | -76.41% | -83.08% | -83.08% | -83.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+7.4% Q4'25: +10.0% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+82.8% ★ Q4'25: -16.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-1.3% Q4'25: -1.6% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+1.1% Q4'25: +1.8% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+1.2% Q4'25: +2.3% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q4'25: +0.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×6.82× Q4'25: 4.02× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 4 Rev. Ana. 2 EPS Ana. |
Jun 2027 4 Rev. Ana. 3 EPS Ana. |
Jun 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
76.57M
est: 74.65M (+2.6%)
|
107.57M
est: 108.25M (-0.6%)
|
162.15M
est: 163.30M (-0.7%)
|
155.02M
est: 153.64M (+0.9%)
|
166.46M
est: 165.29M (+0.7%)
|
171.27M
167.09M – 176.15M
+3.6% YoY
|
182.93M
177.82M – 186.93M
+6.8% YoY
|
195.67M
194.86M – 196.47M
+7.0% YoY
|
| EBITDA |
3.46M
est: 1.46M (+136.6%)
|
5.14M
est: 2.12M (+142.7%)
|
14.16M
est: 3.20M (+342.8%)
|
-20.36M
est: 3.01M (-776.8%)
|
8.14M
est: 3.24M (+151.6%)
|
3.35M
3.27M – 3.45M
+3.6% YoY
|
3.58M
3.48M – 3.66M
+6.8% YoY
|
3.83M
3.81M – 3.85M
+7.0% YoY
|
| EBIT |
2.08M
est: -712.7K (+391.3%)
|
2.91M
est: -1.03M (+381.8%)
|
8.80M
est: -1.56M (+664.1%)
|
-26.57M
est: -1.47M (-1,711.4%)
|
1.80M
est: -1.58M (+213.8%)
|
-1.64M
-1.68M – -1.60M
-3.6% YoY
|
-1.75M
-1.78M – -1.70M
-6.8% YoY
|
-1.87M
-1.88M – -1.86M
-7.0% YoY
|
| Net Income |
1.88M
est: 5.94M (-68.3%)
|
1.70M
est: 4.95M (-65.6%)
|
1.89M
est: 10.21M (-81.5%)
|
-25.33M
est: -4.06M (-524.3%)
|
-4.46M
est: -4.46M (+0.0%)
|
3.16M
2.91M – 5.99M
+170.7% YoY
|
4.87M
-2.74M – 16.91M
+54.3% YoY
|
10.07M
7.81M – 16.45M
+107.0% YoY
|
| SGA |
26.01M
est: 23.16M (+12.3%)
|
32.51M
est: 33.59M (-3.2%)
|
47.70M
est: 50.67M (-5.9%)
|
49.97M
est: 47.67M (+4.8%)
|
48.78M
est: 51.29M (-4.9%)
|
53.14M
51.84M – 54.66M
+3.6% YoY
|
56.76M
55.17M – 58.00M
+6.8% YoY
|
60.71M
60.46M – 60.96M
+7.0% YoY
|
| EPS |
0.01
est: 0.04 (-62.8%)
|
0.01
est: 0.03 (-74.8%)
|
0.01
est: 0.07 (-81.5%)
|
-0.17
est: -0.03 (-537.5%)
|
-0.03
est: 0.04 (-180.3%)
|
0.03
0.02 – 0.04
-26.0% YoY
|
0.06
-0.02 – 0.11
+121.0% YoY
|
0.08
0.05 – 0.11
+33.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Tomisich | Founder, Chief Executive Officer, MD & Executive Director | 634.9K | male |
| Nigel Gilligan | Chief Operations Officer | 395.7K | male |
| Robert Lyon | Executive Director, Head of Corporate Development & General Counsel | 374.7K | male |
| Alister John Hodges | CFO & Joint Company Secretary | 363.9K | male |
| Andrew Arthur Gooley | Chief Scientific Officer | 336.6K | — |
| Helene Lajoie | Chief Human Resources Officer | — | female |
| Simon Billingham | Interim CFO & Interim Joint Company Secretary | — | male |
| Rebecca Wilson | Investor Relations Advisor | — | female |
| Marie Krstic | Head of Corporate Communications & Investor Relations | — | female |
| Mark Andrew Licciardo FCIS FGIA GAICD | Joint Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRJ.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
